| Drug Treatment For Parkinson's Disease Outlined By Henry Ford Neurologist In NEJM |
| Levodopa has long been proven to provide the greatest relief of all available medications in the treatment of Parkinson's disease. It also is the most cost-effective drug for managing the full range of problems associated with this chronic neurological disorder, which affects an estimated one million Americans. In the Dec. 4 issue of the New England Journal of Medicine, Henry Ford Hospital neurologist Peter A. LeWitt, M.D.
12/04/2008
|
| Schering Plough Reports Preladenant Meets Primary Endpoint In Phase II Dose-Finding Trial For Parkinson's Disease |
| Schering-Plough Corporation (NYSE: SGP) reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented at the company's 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.
11/28/2008
|
| Ceregene Announces Clinical Data From Phase 2 Clinical Trial Of CERE-120 For Parkinson's Disease |
| Ceregene, Inc., a biopharmaceutical company, reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not demonstrate an appreciable difference between patients treated with CERE-120 versus those in the control group.
11/27/2008
|
| Genetics Of Parkinson's Disease Clarified By New Research |
| A new study by Narendra et al. suggests that Parkin, the product of the Parkinson's disease-related gene Park2, prompts neuronal survival by clearing the cell of its damaged mitochondria. "[This is] an exciting new discovery that links the fields of mitochondrial quality control and the genetics of Parkinson's disease (PD)," writes Heidi McBride of the University of Ottawa Heart Institute.
11/25/2008
|
| Schering Plough Reports Preladenant Meets Primary Endpoint In Phase II Dose-Finding Trial For Parkinson's Disease |
| Schering-Plough Corporation (NYSE: SGP) reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented at the company's 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.
11/25/2008
|
| Stem Cell Collection For Parkinson's Disease Therapy: Jefferson Researchers Define Ideal Time |
| Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson's disease, according to data presented at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience. Lorraine Iacovitti, Ph.D.
11/20/2008
|
| Researchers Define Ideal Time For Stem Cell Collection For Parkinson's Disease Therapy |
| Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson's disease, according to data presented at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience. Lorraine Iacovitti, Ph.D.
11/20/2008
|
| Curry Spice Curcumin And Parkinson's Disease? Protects Against A53T Alpha-synuclein-induced Toxicity |
| Johns Hopkins Researchers at Neuroscience 2008 - Curcumin, derived from the curry spice turmeric, has strong antioxidant and anti-inflammatory properties. Both oxidative damage - damage caused by oxygen - and inflammation have been implicated in nerve cell death associated with Parkinson's disease. Now, researchers at the Johns Hopkins University School of Medicine have shown in a laboratory model of Parkinson's disease that curcumin does protect cells from dying.
11/18/2008
|
| Mayo Clinic Develops Potential New Therapy To Stop The Progression Of Parkinson's Disease |
| Mayo Clinic (http://www.mayoclinic.org) researchers have developed a method to reduce the production of alpha-synuclein in the brain. Alpha-synuclein is a protein that is believed to be central to the cause of Parkinson's disease (http://www.mayoclinic.org/parkinsons- disease).
11/18/2008
|
| Alzheimer's, Parkinson's Diseases Could Be Halted By Protecting Neurons |
| Researchers at Southern Methodist University (SMU) and The University of Texas at Dallas (UTD) have identified a group of chemical compounds that slow the degeneration of neurons, a condition behind old-age diseases like Alzheimer's, Parkinson's and amyotrophic lateral sclerosis (ALS). Their findings are featured in the November 2008 edition of Experimental Biology and Medicine. SMU Chemistry Professor Edward R.
11/16/2008
|
| A Window Into Parkinson's Disease |
| A new study being published in this Friday's online edition of Cell will help answer the question, what causes Parkinson's disease? One of the most pressing questions in the medical research into Parkinson's disease is what causes the sensitive cells in the brain to die in the first place.
11/14/2008
|
| £2 Million Clinical Trials Funding For Alzheimer's And Parkinson's Research |
| Researchers from the Peninsula Medical School, Plymouth Hospitals NHS Trust and the University of Plymouth, have received a grant funding of £2million over the next five years from the National Institute for Health Research (NIHR) to investigate new ways of developing clinical trials for the treatment of Alzheimer's disease and Parkinson's disease.
11/12/2008
|
| UK Experts Warn About Untested Remedies And Issue Guide To Consumers |
| Medical experts from UK charities concerned about the rise in miracle cure stories, wonder drugs and so-called breakthrough therapies have teamed up to produce a guide that explains how to tell the beneficial from the bogus.
11/11/2008
|
| Alnylam And Collaborators Publish New Pre-Clinical Research On Therapeutic Silencing Of Key Gene Implicated In Parkinson's Disease |
| Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has published new research with collaborators at Mayo Clinic in the journal Molecular Neurodegeneration. The new pre-clinical findings demonstrate durable therapeutic silencing of the alpha-synuclein gene when small interfering RNAs (siRNAs), the molecules that mediate RNAi, are administered by direct delivery to the CNS in mice.
11/05/2008
|
| Treatment For Gout And The Condition's Protective Effects |
| The goal in treating patients with gout is to reduce acute attacks by lowering serum urate levels, which are usually high in this disease. At the same time, high serum urate levels have been shown to lower the risk of developing Parkinson's disease (PD). A new study compared the safety and efficacy of febuxostat, a new drug being developed for gout that was recently approved for use in Europe, and a commonly used drug that has been around for years.
11/05/2008
|
